Stock Scorecard
Stock Summary for Cellectis (CLLS) - $2.98 as of 6/22/2026 1:24:28 PM EST
Total Score
7 out of 30
Safety Score
17 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CLLS
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CLLS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CLLS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CLLS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CLLS (17 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for CLLS
Financial Details for CLLS
Company Overview |
|
|---|---|
| Ticker | CLLS |
| Company Name | Cellectis |
| Country | N/A |
| Description | Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | 8/3/2026 |
Stock Price History |
|
| Last Day Price | 2.98 |
| Price 4 Years Ago | 2.10 |
| Last Day Price Updated | 6/22/2026 1:24:28 PM EST |
| Last Day Volume | 163,492 |
| Average Daily Volume | 46,252 |
| 52-Week High | 5.48 |
| 52-Week Low | 1.35 |
| Last Price to 52 Week Low | 120.74% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 24.84 |
| Sector PE | 47.44 |
| 5-Year Average PE | -6.07 |
| Free Cash Flow Ratio | 6.21 |
| Industry Free Cash Flow Ratio | 17.24 |
| Sector Free Cash Flow Ratio | 30.20 |
| Current Ratio Most Recent Quarter | 1.52 |
| Total Cash Per Share | 0.48 |
| Book Value Per Share Most Recent Quarter | 0.82 |
| Price to Book Ratio | 5.21 |
| Industry Price to Book Ratio | 5.90 |
| Sector Price to Book Ratio | 12.21 |
| Price to Sales Ratio Twelve Trailing Months | 4.23 |
| Industry Price to Sales Ratio Twelve Trailing Months | 8.34 |
| Sector Price to Sales Ratio Twelve Trailing Months | 23.47 |
| Analyst Buy Ratings | 2 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 72,611,000 |
| Market Capitalization | 216,380,780 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -83.87% |
| Reported EPS 12 Trailing Months | -0.67 |
| Reported EPS Past Year | -0.18 |
| Reported EPS Prior Year | -0.62 |
| Net Income Twelve Trailing Months | -67,293,573 |
| Net Income Past Year | -67,593,000 |
| Net Income Prior Year | -36,761,000 |
| Quarterly Revenue Growth YOY | -37.30% |
| 5-Year Revenue Growth | -0.27% |
| Operating Margin Twelve Trailing Months | -333.40% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 35,001,000 |
| Total Cash Past Year | 63,581,000 |
| Total Cash Prior Year | 143,251,000 |
| Net Cash Position Most Recent Quarter | -16,640,000 |
| Net Cash Position Past Year | 12,364,000 |
| Long Term Debt Past Year | 51,217,000 |
| Long Term Debt Prior Year | 43,990,000 |
| Total Debt Most Recent Quarter | 51,641,000 |
| Equity to Debt Ratio Past Year | 0.60 |
| Equity to Debt Ratio Most Recent Quarter | 0.54 |
| Total Stockholder Equity Past Year | 75,901,000 |
| Total Stockholder Equity Prior Year | 131,033,000 |
| Total Stockholder Equity Most Recent Quarter | 59,920,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -40,142,300 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.55 |
| Free Cash Flow Past Year | -42,504,110 |
| Free Cash Flow Prior Year | 19,524,450 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 3.00 |
| 20-Day Bollinger Middle Band | 3.69 |
| 20-Day Bollinger Upper Band | 4.39 |
| Beta | 2.75 |
| RSI | 29.01 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 2.58 |
| 200-Day SMA | 2.54 |
System |
|
| Modified | 6/22/2026 8:16:46 PM EST |